The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis c virus among illicit drug users: A modeling study

Iranian Red Crescent Medical Journal

Volumn 16, Issue 2, 2014, Pages

  Javanbakht, Mehdi ^a,b   Mirahmadizadeh, Alireza ^c   Mashayekhi, Atefeh ^d  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C virus; Illicit drug users; Iran; Markov model; Methadone maintenance treatment; Quality adjusted life years

Indexed keywords

ILLICIT DRUG;

ADULT; ARTICLE; DRUG ABUSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIDDEN MARKOV MODEL; HIGH RISK BEHAVIOR; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; METHADONE TREATMENT; MONTE CARLO METHOD; MORBIDITY; MORTALITY; NONHUMAN; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; UNSAFE SEX;

EID: 84895799242     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: 10.5812/ircmj.13484     Document Type: Article

References (58)

1. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyn-iak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83.
2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specifc fbrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-31.
3. Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najaf A, Rahim-nia R, Asgari F, et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol. 2012;157(10):1959-65.
4. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ah-Madian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009;86(6):902-8.
5. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-14.
6. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepa-tology. 1997;26(3 Suppl 1):15S-20S.
7. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol. 2005;20(7):1082-6.
8. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352-8.
9. Alavian SM, Ahmadzad-Asl M, Lankarani KB, Shahbabaie MA, Bah-rami Ahmadi A, Kabir A. Hepatitis C infection in the general population of Iran: a systematic review. Hepat Mon. 2009;9(3):211-23.
10. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the frst population-based study from Iran. Int J Infect Dis. 2010;14 Suppl 3:e113-6.
11. Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, et al. Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors. Int J Prev Med. 2012;3(Suppl 1):S131-8.
12. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Es-maeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis. 2010;14(1):e28-33.
13. Gibson DR, Flynn NM, McCarthy JJ. Efectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999;13(14):1807-18.
14. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997;92(8):999-1005.
15. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Pal-mateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-88.
16. Baraz P, Sayadi N, Shahbazian H, Latif M, Karimi M. Examination with Two Types of Semmes Weinstein Monoflaments as Screening Tools for Diabetic Peripheral Neuropathy. Iran J Endocrin Metab. 2012;14(4).
17. Boghrabadi V, Hejazi SM, Sanian H, Hoseinzadeh A, Motejaded R, Sardar MA. The Impact of Regular Aerobic Exercise on the Levels of Leptin, Fasting Blood Glucose, Insulin and Insulin Resistance in Patients with Diabetes Mellitus Type 2. Life Scie J. 2012;9(3).
18. Sheerin IG, Green FT, Sellman JD. What is the cost-efectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev. 2004;23(3):261-72.
19. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-efectiveness of methadone maintenance. Am J Public Health. 2000;90(7):1100-11.
20. Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A, et al. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon. 2013;13(8).
21. Rehle T, Saidel T, Mills S, Magnani R, Rodgers AB, Crawley H, et al. Evaluating programs for HIV/AIDS prevention and care in developing countries: a handbook for program managers and decision makers. Forced Migration Review. 2000;18(9):4.
22. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost-efectiveness Analysis in Healthcare. London: Oxford University Press; 2011.
23. Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: a review article. J Ophthalmic Vis Res. 2008;3(1):52-65.
24. Hosseini M, SeyedAlinaghi S, Kheirandish P, Esmaeli Javid G, Shirzad H, Karami N, et al. Prevalence and correlates of co-infection with human immunodefciency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med. 2010;13(4):318-23.
25. De Carli G, Puro V, Ippolito G, Studio Italiano Rischio Occupazio-nale da H. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection. 2003;31 Suppl 2:22-7.
26. Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol. 2007;36(2):396-405.
27. Bayoumi AM, Zaric GS. The cost-efectiveness of Vancouver's supervised injection facility. CMAJ. 2008;179(11):1143-51.
28. Wejstal R. Sexual transmission of hepatitis C virus. J hepatol. 1999;31:92-5.
29. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881-9.
30. Weller S, Davis K. Condom efectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002(1):CD003255.
31. Holmes KK, Levine R, Weaver M. Efectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454-61.
32. Thein HH. Estimating the Prognosis of Canadians Infected With the Hepatitis C Virus Through the Blood Supply, 1986-1990.; 2011.
33. Werb D, Wood E, Kerr T, Hershfeld N, Palmer RW, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. Int J Drug Policy. 2011;22(1):70-6.
34. Krahn MD, John-Baptiste A, Yi Q, Doria A, Remis RS, Ritvo P, et al. Potential cost-efectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine. 2005;23(13):1549-58.
35. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology. 2005;42(3):711-23.
36. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hick-man M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(2):102-23.
37. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodefciency virus (HIV) infection on the progression of liver fbrosis in hepatitis C virus infected patients. Gut. 2003;52(7):1035-40.
38. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Pei-gnoux M, et al. The infuence of human immunodefciency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34(6):1193-9.
39. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Infuence of human immunodefciency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33(4):562-9.
40. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defc Syndr. 2008;47(2):221-5.
41. Lashkaripour K, Bakhshani NM, Sadjadi SA. Quality of life in patients on methadone maintenance treatment: a three-month assessment. J Pak Med Assoc. 2012;62(10):1003-7.
42. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Na-glie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630-8.
43. Sutton AJ, Edmunds WJ, Sweeting MJ, Gill ON. The cost-efec-tiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat. 2008;15(11):797-808.
44. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost efectiveness of interferon alpha or peginter-feron alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006;55(9):1332-8.
45. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. In-terferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2007;11(11):1-205.
46. Craine N, Hickman M, Parry JV, Smith J, Walker AM, Russell D, et al. Incidence of hepatitis C in drug injectors: the role of home-lessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect. 2009;137(9):1255-65.
47. Ghorbani R, Naeini BA, Eskandarian R, Rashidy-Pour A, Kham-seh ME, Malek M. Prevalence of metabolic syndrome according to ATPIII and IDF criteria in the Iranian population. Koomesh. 2012;14(1):Pe65-Pe75.
48. Bruce RD. Methadone as HIV prevention: high volume metha-done sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy. 2010;21(2):122-4.
49. Heydari B, Yaghoubi G, Yaghoubi MA, Miri MR. Prevalence and risk factors for diabetic retinopathy: an Iranian eye study. Eur J 50. Ophthalmol. 2012;22(3):393-7.
50. Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Mills S, et al. Cost-efectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care. 2012;24(3):283-90.
51. Roy E, Haley N, Leclerc P, Boivin JF, Cedras L, Vincelette J. Risk factors for hepatitis C virus infection among street youths. CMAJ. 2001;165(5):557-60.
52. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004;33(1):182-8.
53. Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect. 2003;79(2):160-2.
54. Alary M, Joly JR, Vincelette J, Lavoie R, Turmel B, Remis RS. Lack of evidence of sexual transmission of hepatitis C virus in a pro-spective cohort study of men who have sex with men. Am J Public Health. 2005;95(3):502-5.
55. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002;14(5):367-78.
56. Novick DM, Richman BL, Friedman JM, Friedman JE, Fried C, Wilson JP, et al. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend. 1993;33(3):235-45.
57. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981;30(3):353-62.
58. Novick DM. The impact of hepatitis C virus infection on metha-done maintenance treatment. Mt Sinai J Med. 2000;67(5-6):437-43.